Compare Organon & Co. Common Stock (OGN) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while iShares 1 3 Year Treasury Bond ETF trades at $81.31 (market cap $26.87B). The key difference: iShares 1 3 Year Treasury Bond ETF is far larger — about 7.4× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares 1 3 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and iShares 1 3 Year Treasury Bond ETF for 64 Days on average.
| OGN | SHY | |
|---|---|---|
Market Cap | $3.62B | $26.87B |
Volume | 2,892,999 | 3,180,822 |
Sector | Health | Fixed Income |
52-Week High | $13.81 | $83.18 |
52-Week Low | $5.70 | $81.05 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SHY, a US stock, trades at $81.19 with minimal daily movement, reflecting stability amid broader bond market volatility. Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent dividend actions provide income, but key financial ratios are unavailable. The stock's price action is tightly range-bound with support and resistance near $81.
The outlook for SHY is cautious due to bearish technical signals and a lack of fundamental data. Risks include interest rate sensitivity and macroeconomic pressures from rising bond yields. Investment opportunities may lie in its dividend yield if fundamentals strengthen, but current sentiment and technicals suggest limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
